<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913939</url>
  </required_header>
  <id_info>
    <org_study_id>UHN REB 09-0026-C</org_study_id>
    <nct_id>NCT00913939</nct_id>
  </id_info>
  <brief_title>High-Dose-Rate Brachytherapy</brief_title>
  <official_title>MRI-Guided HDR Brachytherapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study initiates a research program testing the early technical and clinical
      performance of a novel procedure for MRI-guided high-dose-rate (HDR) prostate brachytherapy.
      Testing will proceed in two cohorts of patients. In Arm 1, patients with locally recurrent
      prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm
      1 of the study will be coordinated and closely integrated with a separate concurrent study of
      MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial
      (UHN 05-0641-C). In arm 2, patients with locally advanced prostate cancer will receive a
      boost of prostate-targeted HDR brachytherapy during external beam radiotherapy.

      This technique will be prospectively evaluated in up to 100 patients. Preliminary data
      acquired in this pilot study will determine the technical limits of MRI guided HDR
      brachytherapy and will be critical for the judicious conduct of a subsequent phase II
      clinical trial.

      This proposal is innovative in two fundamental ways: MRI-guidance, and specific tumor
      targeting for HDR brachytherapy. Successful completion of this study will further
      individualize local therapy, not only for the benefit of the proportion of cancer patients
      for whom initial radiotherapeutic interventions have failed, but also provide valuable
      technical and clinical validation that these novel image-guided (IG) approaches are
      clinically feasible and could be applied more broadly in prostate cancer therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two hundred and nineteen thousand new cases of prostate cancer have been projected in the
      Unites States for 2007, with external beam radiotherapy (EBRT) constituting the mainstay of
      local therapy for an increasing proportion of newly diagnosed patients. Despite improvements
      in the delivery and reduction in associated toxicity of external beam radiotherapy, local
      persistence or recurrence of disease remains prevalent in 25-51% of patients. Local disease
      after EBRT is a risk factor for subsequent metastatic progression and prostate
      cancer-specific mortality, and is a cause of morbidity including hematuria, obstructive
      uropathy, and chronic pain. Given its prevalence, and the lack of satisfactory local salvage
      treatments, fear of prostate cancer recurrence has been shown to impose a substantial burden
      of suffering in patients.

      Stereotactic needle placement under MRI-guidance enables two critical steps in tumor-targeted
      brachytherapy: 1) directly guiding brachytherapy catheters to sites of tumor recurrence, and
      2) permitting treatment planning and delivery to be based on 3D MRI images. MRI-based HDR
      brachytherapy will precisely identify the location of brachytherapy catheters relative to the
      target volumes and adjacent normal structures at risk of radiation injury, obviating the need
      for invasive saturation (24-100) mapping biopsies.

      This study will build the evidence supporting the concept of MRI-guidance and tumor-targeted
      HDR brachytherapy in the management of prostate cancer. This trial will strive to demonstrate
      improvements in technical performance under MRI-guidance, while exploring a novel paradigm of
      patient-specific modulation of dose intensity based on regions of tumor burden.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if MRI-guided HDR brachytherapy is associated with favorable measures of technical performance.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine if prostate targeted &amp; MRI-guided HDR BT is associated with favorable preliminary measures of clinical performance as boost to EBRT;if tumor-targeted &amp; MRI-guided HDR BT is associated with favorable preliminary measures of clinical performance</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine dose-response relationships for salvage brachytherapy with a 20% escalation in dose.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Patients With Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1: Salvage After EBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with locally recurrent prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm 1 of the study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial (UHN 05-0641-C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Boost to EBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with locally advanced prostate cancer will receive a boost of prostate-targeted HDR brachytherapy during external beam radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI Guided Needles to deliver HDR Brachytherapy</intervention_name>
    <description>Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).</description>
    <arm_group_label>1: Salvage After EBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI Guided Needles to deliver HDR Brachytherapy</intervention_name>
    <description>Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.</description>
    <arm_group_label>2: Boost to EBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior enrollment of UHN 05-0641-C or UHN 12-5015-C (Arm 1)

          -  Histological evidence of recurrent prostate adenocarcinoma (Arm 1)

          -  PSA doubling time &gt; 6 months (Arm 1)

          -  High-risk localized prostate cancer (&gt;T2 or G&gt;7 or PSA&gt;20) (Arm 2)

          -  Planned for EBRT + HDR boost (+/- hormone therapy) (Arm 2)

          -  ECOG 0 or 1

          -  Age &gt; 18 years

          -  Informed consent: All patients must sign a document of informed consent indicating
             their understanding of the investigational nature and risks of the study before any
             protocol related studies are performed.

        Exclusion Criteria:

          -  Radiological evidence of regional or distant metastases

          -  Contraindications to MRI (Patient weighing &gt;136kg (scanner weight limit), Patients
             with pacemakers, cerebral aneurysm clips, shrapnel injury, or implantable electronic
             devices not compatible with MRI)

          -  Bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased
             during brachytherapy

          -  Previous prostate brachytherapy

          -  Active hormonal therapy (Arm 1)

             -&gt;50% of contiguous sextants involved with tumor (Arm 1)

          -  Previous pelvic radiotherapy (Arm 2)

          -  Contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or
             colorectal surgery.

          -  Latex Allergy

          -  Contraindications to conscious sedation, local anesthesia, or spinal/epidural
             anesthesia.

          -  IPSS &gt;18

          -  Large TURP defect

          -  TURP within the past 6 months

          -  Prostate gland size &gt;80cc

          -  History of Ulcerative Colitis, Crohn's Disease, Ataxia Telangiectasia, or SLE

          -  Other medical conditions deemed by the PI to make patient ineligible for MRI-guided
             Prostate HDR brachytherapy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Chung, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Princess Margaret Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Chung, MB ChB</last_name>
    <phone>416 946 4501</phone>
    <phone_ext>6522</phone_ext>
    <email>Peter.chung@rmp.uhn.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia MÃ©nard, MD</last_name>
    <phone>514 890-8000</phone>
    <phone_ext>24684</phone_ext>
    <email>cynthia.menard.chum@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network, Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Chung, MB ChB</last_name>
      <phone>416 946 4501</phone>
      <phone_ext>6522</phone_ext>
      <email>Peter.Chung@rmp.uhn.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>HDR Brachytherapy</keyword>
  <keyword>Prostate Brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

